Literature DB >> 19635528

Effects of rolipram on adult rat oligodendrocytes and functional recovery after contusive cervical spinal cord injury.

E Beaumont1, C M Whitaker, D A Burke, M Hetman, S M Onifer.   

Abstract

Traumatic human spinal cord injury (SCI) causes devastating and long-term hardships. These are due to the irreparable primary mechanical injury and secondary injury cascade. In particular, oligodendrocyte cell death, white matter axon damage, spared axon demyelination, and the ensuing dysfunction in action potential conduction lead to the initial deficits and impair functional recovery. For these reasons, and that oligodendrocyte and axon survival may be related, various neuroprotective strategies after spinal cord injury are being investigated. We previously demonstrated that oligodendrocytes in the adult rat epicenter ventrolateral funiculus (VLF) express 3'-5'-cyclic adenosine monophosphate-dependent phosphodiesterase 4 (PDE4) subtypes and that their death was attenuated up to 3 days after contusive cervical SCI when rolipram, a specific inhibitor of PDE4, was administered. Here, we report that (1) there are more oligodendrocyte somata in the adult rat epicenter VLF, (2) descending and ascending axonal conductivity in the VLF improves, and that (3) there are fewer hindlimb footfall errors during grid-walking at 5 weeks after contusive cervical SCI when rolipram is delivered for 2 weeks. This is the first demonstration of improved descending and ascending long-tract axonal conductivity across a SCI with this pharmacological approach. Since descending long-tract axonal conductivity did not return to normal, further evaluations of the pharmacokinetics and therapeutic window of rolipram as well as optimal combinations are necessary before consideration for neuroprotection in humans with SCI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635528      PMCID: PMC2760664          DOI: 10.1016/j.neuroscience.2009.07.039

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  30 in total

1.  Functional redundancy of ventral spinal locomotor pathways.

Authors:  David N Loy; David S K Magnuson; Y Ping Zhang; Stephen M Onifer; Michael D Mills; Qi-lin Cao; Jessica B Darnall; Lily C Fajardo; Darlene A Burke; Scott R Whittemore
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

2.  Delayed antagonism of AMPA/kainate receptors reduces long-term functional deficits resulting from spinal cord trauma.

Authors:  J R Wrathall; Y D Teng; R Marriott
Journal:  Exp Neurol       Date:  1997-06       Impact factor: 5.330

3.  A sensitive and reliable locomotor rating scale for open field testing in rats.

Authors:  D M Basso; M S Beattie; J C Bresnahan
Journal:  J Neurotrauma       Date:  1995-02       Impact factor: 5.269

4.  Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination.

Authors:  R P Bunge; W R Puckett; J L Becerra; A Marcillo; R M Quencer
Journal:  Adv Neurol       Date:  1993

5.  Jaw muscle response to stimulation of type II somatosensory afferents of limbs in the rat.

Authors:  F Deriu; M Milia; M V Podda; G Chessa; E Tolu
Journal:  Exp Brain Res       Date:  2001-07       Impact factor: 1.972

6.  Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury.

Authors:  K C Hayes; A R Blight; P J Potter; R D Allatt; J T Hsieh; D L Wolfe; S Lam; J T Hamilton
Journal:  Paraplegia       Date:  1993-04

7.  Anatomical correlates of locomotor recovery following dorsal and ventral lesions of the rat spinal cord.

Authors:  P Schucht; O Raineteau; M E Schwab; K Fouad
Journal:  Exp Neurol       Date:  2002-07       Impact factor: 5.330

8.  The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery.

Authors:  Elena Nikulina; J Lille Tidwell; Hai Ning Dai; Barbara S Bregman; Marie T Filbin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

9.  cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury.

Authors:  Damien D Pearse; Francisco C Pereira; Alexander E Marcillo; Margaret L Bates; Yerko A Berrocal; Marie T Filbin; Mary Bartlett Bunge
Journal:  Nat Med       Date:  2004-05-23       Impact factor: 53.440

10.  Gradual loss of myelin and formation of an astrocytic scar during Wallerian degeneration in the human spinal cord.

Authors:  A Buss; G A Brook; B Kakulas; D Martin; R Franzen; J Schoenen; J Noth; A B Schmitt
Journal:  Brain       Date:  2003-10-08       Impact factor: 13.501

View more
  16 in total

1.  Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury.

Authors:  C M Atkins; Y Kang; C Furones; J S Truettner; O F Alonso; W D Dietrich
Journal:  J Neurosci Res       Date:  2012-04-26       Impact factor: 4.164

Review 2.  Oligodendrocyte fate after spinal cord injury.

Authors:  Akshata Almad; F Rezan Sahinkaya; Dana M McTigue
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

3.  Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia.

Authors:  Scott A Myers; Leila Gobejishvili; Sujata Saraswat Ohri; C Garrett Wilson; Kariena R Andres; Amberly S Riegler; Hridgandh Donde; Swati Joshi-Barve; Shirish Barve; Scott R Whittemore
Journal:  Neurobiol Dis       Date:  2018-12-14       Impact factor: 5.996

4.  A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes, and tissue damage after spinal cord injury.

Authors:  Feng Bao; Jennifer C Fleming; Roozbeh Golshani; Damien D Pearse; Levent Kasabov; Arthur Brown; Lynne C Weaver
Journal:  J Neurotrauma       Date:  2011-05-05       Impact factor: 5.269

5.  Drug-eluting microfibrous patches for the local delivery of rolipram in spinal cord repair.

Authors:  Timothy L Downing; Aijun Wang; Zhi-Qiang Yan; Yvette Nout; Andy L Lee; Michael S Beattie; Jacqueline C Bresnahan; Diana L Farmer; Song Li
Journal:  J Control Release       Date:  2012-05-23       Impact factor: 9.776

6.  PTEN inhibitor bisperoxovanadium protects oligodendrocytes and myelin and prevents neuronal atrophy in adult rats following cervical hemicontusive spinal cord injury.

Authors:  Chandler L Walker; Xiao-Ming Xu
Journal:  Neurosci Lett       Date:  2014-02-26       Impact factor: 3.046

7.  Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival.

Authors:  E M Medina-Rodríguez; F J Arenzana; J Pastor; M Redondo; V Palomo; R García de Sola; C Gil; A Martínez; A Bribián; F de Castro
Journal:  Cell Mol Life Sci       Date:  2013-05-10       Impact factor: 9.261

8.  The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.

Authors:  Sandra Marie Schaal; Maneesh Sen Garg; Mousumi Ghosh; Lilie Lovera; Michael Lopez; Monal Patel; Jack Louro; Samik Patel; Luis Tuesta; Wai-Man Chan; Damien Daniel Pearse
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

9.  Lipidic nanocapsule drug delivery: neuronal protection for cochlear implant optimization.

Authors:  Hartwig Meyer; Timo Stöver; Florian Fouchet; Guillaume Bastiat; Patrick Saulnier; Wolfgang Bäumer; Thomas Lenarz; Verena Scheper
Journal:  Int J Nanomedicine       Date:  2012-05-15

10.  Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination.

Authors:  Yasir A Syed; Alexandra Baer; Matthias P Hofer; Ginez A González; Jon Rundle; Szymon Myrta; Jeffrey K Huang; Chao Zhao; Moritz J Rossner; Matthew W B Trotter; Gert Lubec; Robin J M Franklin; Mark R Kotter
Journal:  EMBO Mol Med       Date:  2013-10-21       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.